However, previous reports have demonstrated that inflammatory mediators associated with activation of IL-17 axis, IL-6 specifically, can regulate NAFLD pathogenesis in part via regulation of lipogenic machinery [28]. This evidence concerns the gene IL6 and metabolic dysfunction-associated steatotic liver disease.